Table 1 Antimicrobial susceptibility of major uropathogens causing community-acquired urinary tract among the paediatric patients

Amikacin

S ≤ 16, R ≥ 64

43 (79.6%)

2

64

 ≤ 2 to ≥ 64

7 (100%)

2

32

 ≤ 2 to ≥ 64

Amoxicillin-clavulanic acid

S ≤ 8/4, R ≥ 32/16

27 (50%)

16

32

 ≤ 2 to ≥ 32

5 (71.4%)

8

–

 ≤ 2 to ≥ 32

Ampicillin

S ≤ 8, R ≥ 32

15 (27.7%)

32

32

 ≤ 2 to ≥ 32

1 (14.2%)

32

32

 ≤ 2 to ≥ 32

Cefalotin

S ≤ 16, R ≥ 32

16 (29.6%)

64

64

 ≤ 2 to ≥ 64

4 (57%)

4

–

 ≤ 2 to ≥ 64

Cefixime

S ≤ 1, R ≥ 4

20 (37%)

4

4

 ≤ 0.25 to ≥ 4

7 (100%)

0.25

4

 ≤ 0.25 to ≥ 4

Cefoxitin

S ≤ 8, R ≥ 32

34 (63%)

4

64

 ≤ 2 to ≥ 64

4 (57%)

4

–

 ≤ 4 to ≥ 64

Ceftazidime

S ≤ 4, R ≥ 16

28 (51.8%)

4

64

 ≤ 1 to ≥ 64

3 (42.8%)

1

64

 ≤ 0.5 to ≥ 64

Ceftriaxone

S ≤ 1, R ≥ 4

21 (38.8%)

64

64

 ≤ 1 to ≥ 64

6 (85.7)

1

64

 ≤ 1 to ≥ 64

Ciprofloxacin

S ≤ 0.25, R ≥ 1

17 (31.4%)

4

4

 ≤ 0.25 to ≥ 64

3 (42.8%)

0.25

4

 ≤ 0.25 to ≥ 4

Cotrimoxazole

S ≤ 40, R ≥ 80

29 (53.7%)

20

320

 ≤ 20 to ≥ 320

5 (71.4%)

20

320

 ≤ 20 to ≥ 320

Ertapenem

S ≤ 0.5, R ≥ 2

49 (90.7%)

0.5

0.5

 ≤ 0.5 to ≥ 8

7 (100%)

0.5

–

 ≤ 0.5 to ≥ 8

Fosfomycin

S ≤ 64, R ≥ 256

54 (100%)

16

16

 <  = 16 to ≥ 128

–

–

–

Gentamicin

S ≤ 4, R ≥ 16

37 (68.5%)

1

16

 ≤ 1 to ≥ 16

6 (85.7%)

1

8

 ≤ 1 to ≥ 16

Nitrofurantoin

S ≤ 32, R ≥ 128

48 (88.8%)

16

64

 ≤ 16 to ≥ 256

5 (71.4%)

64

128

 ≤ 16 to ≥ 512

Piperacillin/Tazobactam

S ≤ 32, R > 128

27 (50%)

64

128

 ≤ 4 to ≥ 128

6 (85.7%)

4

128

 ≤ 4 to ≥ 128

Ticarcillin

S ≤ 8, R ≥ 32

14 (26%)

128

128

 ≤ 8 to ≥ 128

0%

128

128

 ≤ 8 to ≥ 128